

Losartan / Hydrochlorothiazide Formulation

Version 7.2 Revision Date: 2025/07/01 SDS Number: 300000000842 Date of last issue: 2023/09/26
Date of first issue: 2014/09/30

SECTION 1. IDENTIFICATION

Product identifier : Losartan / Hydrochlorothiazide Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : Rua Treze de Maio, 1161
Campinas, São Paulo, Brazil 13106-054

Telephone : +1 551-430-6000 US | +55 (19) 3758-2000 BR

Emergency telephone : For 24/7 emergency response advice, call CHEMTREC at +55 11 4349-1359 (local) or 0800 892 0479 (toll-free). Global 24/7: +1-800-424-9300 (United States, English only).

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION**GHS Classification in accordance with ABNT NBR 14725 Standard**

Acute toxicity (Oral) : Category 5

Serious eye damage : Category 1

Skin sensitization : Category 1

Reproductive toxicity : Category 1B

Effects on or via lactation

Specific target organ toxicity - repeated exposure : Category 2 (Kidney, Parathyroid gland)

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Cardio-vascular system, Stomach, Kidney)

GHS label elements in accordance with ABNT NBR 14725 Standard

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H303 May be harmful if swallowed.

Losartan / Hydrochlorothiazide Formulation

Version 7.2 Revision Date: 2025/07/01 SDS Number: 300000000842 Date of last issue: 2023/09/26
 Date of first issue: 2014/09/30

H317 May cause an allergic skin reaction.
 H318 Causes serious eye damage.
 H360D May damage the unborn child.
 H362 May cause harm to breast-fed children.
 H373 May cause damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.
 H373 May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

Precautionary Statements

:

Prevention:

P201 Obtain special instructions before use.
 P260 Do not breathe dust.
 P263 Avoid contact during pregnancy and while nursing.
 P264 Wash skin thoroughly after handling.
 P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of water.
 P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/ doctor.
 P308 + P313 IF exposed or concerned: Get medical advice/ attention.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.
 May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Cellulose	9004-34-6		>= 30 -< 50
Losartan Potassium	124750-99-8	Acute Tox. (Oral), 4 Eye Dam., 1 Skin Sens., 1 Repr., 1B Lact. STOT RE, (Oral)(Blood, Cardio-	>= 20 -< 30

Losartan / Hydrochlorothiazide Formulation

Version 7.2 Revision Date: 2025/07/01 SDS Number: 300000000842 Date of last issue: 2023/09/26
 Date of first issue: 2014/09/30

		vascular system, Stomach, Kidney) , 2	
Starch	9005-25-8		>= 10 -< 20
Hydrochlorothiazide	58-93-5	Acute Tox. (Oral), 5 STOT RE, (Kidney, Parathyroid gland) , 1	>= 1 -< 5

SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.
 Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
 Remove contaminated clothing and shoes.
 Get medical attention.
 Wash clothing before reuse.
 Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
 If easy to do, remove contact lens, if worn.
 Get medical attention immediately.
- If swallowed : If swallowed, DO NOT induce vomiting.
 Get medical attention.
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Contact with dust can cause mechanical irritation or drying of the skin.
 May be harmful if swallowed.
 May cause an allergic skin reaction.
 Causes serious eye damage.
 May damage the unborn child.
 May cause harm to breast-fed children.
 May cause damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray
 Alcohol-resistant foam
 Carbon dioxide (CO₂)
 Dry chemical
- Unsuitable extinguishing : None known.

Losartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
7.2	2025/07/01	300000000842	Date of first issue: 2014/09/30

media

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Chlorine compounds
Sulfur oxides

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Losartan / Hydrochlorothiazide Formulation

Version 7.2 Revision Date: 2025/07/01 SDS Number: 300000000842 Date of last issue: 2023/09/26
 Date of first issue: 2014/09/30

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
 Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Avoid contact during pregnancy and while nursing.
 Do not get on skin or clothing.
 Do not breathe dust.
 Do not swallow.
 Do not get in eyes.
 Wash skin thoroughly after handling.
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
 Keep container tightly closed.
 Minimize dust generation and accumulation.
 Keep container closed when not in use.
 Keep away from heat and sources of ignition.
 Take precautionary measures against static discharges.
 Do not eat, drink or smoke when using this product.
 Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
 When using do not eat, drink or smoke.
 Contaminated work clothing should not be allowed out of the workplace.
 Wash contaminated clothing before re-use.
 The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.
 Store locked up.
 Keep tightly closed.
 Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents
 Self-reactive substances and mixtures
 Organic peroxides
 Explosives
 Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parameters / Permissible	Basis
------------	---------	------------------------	----------------------------------	-------

Losartan / Hydrochlorothiazide Formulation

Version 7.2 Revision Date: 2025/07/01 SDS Number: 300000000842 Date of last issue: 2023/09/26
 Date of first issue: 2014/09/30

		exposure)	concentration	
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
Losartan Potassium	124750-99-8	TWA	100 µg/m ³ (OEB 2)	Internal
Starch	9005-25-8	TWA	10 mg/m ³	ACGIH
Hydrochlorothiazide	58-93-5	TWA	100 µg/m ³ (OEB 2)	Internal

Engineering measures : Use feasible engineering controls to minimize exposure to compound.
 All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : Use respiratory protection unless adequate local exhaust ventilation is provided or exposure assessment demonstrates that exposures are within recommended exposure guidelines.

Filter type : Particulates type

Hand protection
 Material : Chemical-resistant gloves

Eye protection : Wear safety glasses with side shields or goggles.
 If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
 Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Physical state : powder

Color : yellow

Odor : odorless

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Losartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
7.2	2025/07/01	300000000842	Date of first issue: 2014/09/30

Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	Not applicable
Relative vapor density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Autoignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity Viscosity, kinematic	:	Not applicable
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Particle characteristics Particle size	:	No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Losartan / Hydrochlorothiazide Formulation

Version 7.2 Revision Date: 2025/07/01 SDS Number: 300000000842 Date of last issue: 2023/09/26
Date of first issue: 2014/09/30

Information on likely routes of exposure : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

May be harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 2.201 mg/kg
Method: Calculation method

Components:**Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5,8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Losartan Potassium:

Acute oral toxicity : LD50 (Mouse): 1.257 - 1.590 mg/kg
LDLo (Rat): 200 mg/kg
LDLo (Mouse): 400 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Hydrochlorothiazide:

Acute oral toxicity : LD50 (Rat): > 2.750 mg/kg
LD50 (Mouse): > 2.830 mg/kg

Acute toxicity (other routes of administration) : LD50 (Rat): 990 mg/kg
Application Route: Intravenous
LD50 (Mouse): 590 mg/kg
Application Route: Intravenous

Skin corrosion/irritation

Based on available data, the classification criteria are not met.

Losartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
7.2	2025/07/01	300000000842	Date of first issue: 2014/09/30

Components:

Losartan Potassium:

Species	:	Rabbit
Result	:	Mild skin irritation

Hydrochlorothiazide:

Species	:	Rabbit
Result	:	No skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

Components:

Losartan Potassium:

Species	:	Rabbit
Result	:	Severe irritation

Starch:

Species	:	Rabbit
Result	:	No eye irritation

Hydrochlorothiazide:

Species	:	Rabbit
Result	:	Mild eye irritation

Respiratory or skin sensitization

Skin sensitization

May cause an allergic skin reaction.

Respiratory sensitization

Based on available data, the classification criteria are not met.

Components:

Losartan Potassium:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact
Species	:	Guinea pig
Assessment	:	Probability or evidence of skin sensitization in humans
Result	:	positive

Test Type	:	Respiratory sensitization
Remarks	:	No data available

Starch:

Test Type	:	Maximization Test
Routes of exposure	:	Skin contact

Losartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
7.2	2025/07/01	300000000842	Date of first issue: 2014/09/30

Species : Guinea pig
Result : negative

Hydrochlorothiazide:

Remarks : Not classified due to lack of data.

Germ cell mutagenicity

Based on available data, the classification criteria are not met.

Components:

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Losartan Potassium:

Genotoxicity in vitro : Test Type: in vitro test
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster ovary cells
Result: negative

Test Type: Alkaline elution assay
Result: negative

Test Type: Chromosomal aberration
Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration
Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay
Result: negative

Hydrochlorothiazide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay

Losartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
7.2	2025/07/01	300000000842	Date of first issue: 2014/09/30

Result: negative

Test Type: Chromosomal aberration
 Test system: Chinese hamster ovary cells
 Result: negative

Test Type: sister chromatid exchange assay
 Test system: Chinese hamster ovary cells
 Result: positive

Test Type: in vitro test
 Test system: mouse lymphoma cells
 Result: positive

Genotoxicity in vivo : Test Type: Chromosomal aberration
 Species: Chinese hamster
 Cell type: Bone marrow
 Result: negative

Test Type: in vivo assay
 Species: Mouse
 Cell type: Bone marrow
 Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Based on available data, the classification criteria are not met.

Components:

Cellulose:

Species : Rat
 Application Route : Ingestion
 Exposure time : 72 weeks
 Result : negative

Losartan Potassium:

Species : Mouse
 Application Route : Oral
 Exposure time : 92 weeks
 Dose : 200 mg/kg body weight
 Result : negative

Species : Rat
 Application Route : Oral
 Exposure time : 105 weeks
 Dose : 270 mg/kg body weight
 Result : negative

Carcinogenicity - Assess- : Weight of evidence does not support classification as a car-

Losartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
7.2	2025/07/01	300000000842	Date of first issue: 2014/09/30

ment

cinogen

Hydrochlorothiazide:

Species : Mouse, female
 Application Route : Oral
 Exposure time : 2 Years
 Result : negative

Species : Mouse, male
 Application Route : Oral
 Exposure time : 2 Years
 Result : equivocal

Species : Rat, male and female
 Application Route : Oral
 Exposure time : 2 Years
 Result : negative

Carcinogenicity - Assessment : Weight of evidence does not support classification as a carcinogen

Reproductive toxicity

May damage the unborn child.
 May cause harm to breast-fed children.

Components:

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Ingestion
 Result: negative

Losartan Potassium:

Effects on fertility : Test Type: Fertility
 Species: Rat, female
 Application Route: Oral
 Fertility: LOAEL: 200 mg/kg body weight
 Result: female reproductive effects
 Remarks: Maternal toxicity observed.

Effects on fetal development : Test Type: Development
 Species: Rabbit
 Application Route: Oral
 General Toxicity Maternal: NOAEL: 10 mg/kg body weight
 Developmental Toxicity: NOAEL F1: 20 mg/kg body weight

Losartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
7.2	2025/07/01	300000000842	Date of first issue: 2014/09/30

Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, No teratogenic effects.

Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: LOAEL: 10 mg/kg body weight
 Result: Fetotoxicity., No teratogenic effects.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Studies indicating a hazard to babies during the lactation period

Hydrochlorothiazide:

Effects on fertility : Test Type: Fertility
 Species: Rat, male and female
 Application Route: oral (feed)
 Fertility: NOAEL: 4 mg/kg body weight
 Result: Effects on fertility.

Test Type: Fertility
 Species: Mouse, male and female
 Application Route: oral (feed)
 Fertility: NOAEL: 100 mg/kg body weight
 Result: Effects on fertility.

Effects on fetal development : Test Type: Development
 Species: Mouse
 Application Route: Oral
 Developmental Toxicity: NOAEL: 3.000 mg/kg body weight
 Result: No teratogenic effects.

Test Type: Development
 Species: Rat
 Application Route: Oral
 Developmental Toxicity: NOAEL: 1.000 mg/kg body weight
 Result: No teratogenic effects.

Reproductive toxicity - Assessment : Not classified due to data which are conclusive although insufficient for classification.

STOT-single exposure

Based on available data, the classification criteria are not met.

Components:

Losartan Potassium:

Remarks : Not classified

Losartan / Hydrochlorothiazide Formulation

Version 7.2 Revision Date: 2025/07/01 SDS Number: 300000000842 Date of last issue: 2023/09/26
Date of first issue: 2014/09/30

Symptoms : Salivation, Vomiting

Starch:

Species : Rat
NOAEL : ≥ 2.000 mg/kg
Application Route : Skin contact
Exposure time : 28 Days
Method : OECD Test Guideline 410

Hydrochlorothiazide:

Species : Rat, male and female
LOAEL : 10 mg/kg
Application Route : Oral
Exposure time : 2 yr
Target Organs : Kidney, Parathyroid gland

Species : Mouse, male and female
NOAEL : 300 - 550 mg/kg
Application Route : Oral
Exposure time : 2 yr
Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 50 - 200 mg/kg
Application Route : Oral
Exposure time : 9 Months
Target Organs : Parathyroid gland

Aspiration toxicity

Based on available data, the classification criteria are not met.

Components:**Losartan Potassium:**

Not applicable

Hydrochlorothiazide:

Not applicable

Experience with human exposure**Components:****Losartan Potassium:**

Eye contact : Symptoms: Eye irritation
Ingestion : Symptoms: hypotension, tachycardia

Hydrochlorothiazide:

Eye contact : Symptoms: Eye irritation
Ingestion : Symptoms: dizziness, headache, Fatigue, nausea, abdominal

Losartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
7.2	2025/07/01	300000000842	Date of first issue: 2014/09/30

pain, hypotension, dry mouth, electrolyte imbalance, eye pain

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l
 Exposure time: 96 h
 Remarks: Based on data from similar materials

Ecotoxicology Assessment

Acute aquatic toxicity : No toxicity at the limit of solubility.

Losartan Potassium:

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): > 929 mg/l
 Exposure time: 96 h
 Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): 331 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : NOEC (*Microcystis aeruginosa* (blue-green algae)): 949 mg/l
 Exposure time: 10 d
 Method: FDA 4.01

NOEC (*Selenastrum capricornutum* (green algae)): 143 mg/l
 Exposure time: 10 d
 Method: FDA 4.01

Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 10 mg/l
 Exposure time: 32 d
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 100 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211

Hydrochlorothiazide:

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 500 mg/l
 Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): > 500 mg/l
 Exposure time: 48 h

Losartan / Hydrochlorothiazide Formulation

Version 7.2 Revision Date: 2025/07/01 SDS Number: 300000000842 Date of last issue: 2023/09/26
Date of first issue: 2014/09/30

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Losartan Potassium:

Biodegradability : Result: Not biodegradable
Biodegradation: 71 %
Exposure time: 28 d

Stability in water : Hydrolysis: < 10 %(5 d)

Hydrochlorothiazide:

Stability in water : Hydrolysis: 46,2 %(96 h)

Bioaccumulative potential**Components:****Losartan Potassium:**

Partition coefficient: n-octanol/water : log Pow: 1,2

Mobility in soil

No data available

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Losartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
7.2	2025/07/01	300000000842	Date of first issue: 2014/09/30

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation**ANTT**

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH)

Group 2B: Possibly carcinogenic to humans
58-93-5 Hydrochlorothiazide

National List of Carcinogenic Agents for Humans - (LINACH)

Group 2B: Possibly carcinogenic to humans
58-93-5 Hydrochlorothiazide

Brazil. List of chemicals controlled by the Federal Police : Not applicable

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATIONRevision Date : 2025/07/01
Date format : yyyy/mm/dd**Further information**Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

Losartan / Hydrochlorothiazide Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/26
7.2	2025/07/01	300000000842	Date of first issue: 2014/09/30

AIIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

BR / EN